These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37190983)

  • 1. Efficacy of PD-1/PD-L1 inhibitors in advanced gastroesophageal cancer based on characteristics: a meta-analysis.
    Liu W; Huo G; Chen P
    Immunotherapy; 2023 Jul; 15(10):751-771. PubMed ID: 37190983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: A Meta-analysis Including Low PD-L1 Subgroups.
    Yap DWT; Leone AG; Wong NZH; Zhao JJ; Tey JCS; Sundar R; Pietrantonio F
    JAMA Oncol; 2023 Feb; 9(2):215-224. PubMed ID: 36480211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis.
    Huo G; Liu W; Chen P
    BMC Cancer; 2023 Feb; 23(1):143. PubMed ID: 36765356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials.
    Lu Y; Wang W; Wang F
    Front Immunol; 2023; 14():1171671. PubMed ID: 37205107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.
    Zhao JJ; Yap DWT; Chan YH; Tan BKJ; Teo CB; Syn NL; Smyth EC; Soon YY; Sundar R
    J Clin Oncol; 2022 Feb; 40(4):392-402. PubMed ID: 34860570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of PD-1 Inhibitors in First-Line Treatment for Advanced Gastroesophageal Junction and Gastric Cancer by Subgroups: A Systematic Review and Meta-Analysis.
    Fei S; Lu Y; Chen J; Qi J; Wu W; Wang B; Han Y; Wang K; Han X; Zhou H; Wang J; Chen J
    Chemotherapy; 2023; 68(4):197-209. PubMed ID: 37331333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of anti-PD-1/PD-L1 agents vs chemotherapy in patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis.
    Wang BC; Zhang ZJ; Fu C; Wang C
    Medicine (Baltimore); 2019 Nov; 98(47):e18054. PubMed ID: 31764833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials.
    Yoon HH; Jin Z; Kour O; Kankeu Fonkoua LA; Shitara K; Gibson MK; Prokop LJ; Moehler M; Kang YK; Shi Q; Ajani JA
    JAMA Oncol; 2022 Oct; 8(10):1456-1465. PubMed ID: 36006624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis.
    Zhu X; Shanzhou Q; Li D; Pang X; Ma D
    BMC Cancer; 2021 Nov; 21(1):1195. PubMed ID: 34758782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis.
    Li ZC; Sun YT; Lai MY; Zhou YX; Qiu MZ
    Int Immunopharmacol; 2022 Aug; 109():108790. PubMed ID: 35504202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy and adverse reactions analysis of PD-1/PD-L1 inhibitors in advanced esophageal squamous cell carcinoma.
    Wang LL; Xie YX; Liu Y
    Eur Rev Med Pharmacol Sci; 2024 Jan; 28(2):659-667. PubMed ID: 38305608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Programmed Cell Death 1 Inhibitor Monotherapy Versus Chemotherapy as Second-Line Treatment for Advanced Esophageal Cancer: A Meta-analysis and Systematic Review.
    Yang YL; Li ZQ; Wang QL; Gu JJ; Fang XJ; Huang GH
    Clin Ther; 2021 Nov; 43(11):1997-2012. PubMed ID: 34794831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
    Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A practical approach for PD-L1 evaluation in gastroesophageal cancer.
    Angerilli V; Fassan M; Parente P; Gullo I; Campora M; Rossi C; Sacramento ML; Pennelli G; Vanoli A; Grillo F; Mastracci L
    Pathologica; 2023 Apr; 115(2):57-70. PubMed ID: 36537078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitors' combination therapy as first-line treatment in advanced esophageal squamous cell carcinoma: a meta-analysis.
    Li D; Tang L; Hu J; Cao X; He Y
    J Cancer Res Clin Oncol; 2023 Mar; 149(3):933-939. PubMed ID: 35751682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety Profile of PD-1 Inhibitors Versus Chemotherapy in the Second-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Jin Z; Zhao M
    J Immunother; 2023 Sep; 46(7):262-270. PubMed ID: 37338278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncological outcomes of addition of anti-PD1/PD-L1 to chemotherapy in the therapy of patients with advanced gastric or gastro-oesophageal junction cancer: A meta-analysis.
    Zheng Z; Guo Y; Zou CP
    Medicine (Baltimore); 2020 Feb; 99(7):e18332. PubMed ID: 32049776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors for the clinical benefit of anti-PD-1/PD-L1 therapy in advanced gastroesophageal cancer: a meta-analysis of clinical trials.
    Zhuo ZG; Deng HY; Song TN; Alai GH; Shen X; Lin YD
    Ann Palliat Med; 2020 Sep; 9(5):2524-2537. PubMed ID: 33065778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score.
    Leone AG; Petrelli F; Ghidini A; Raimondi A; Smyth EC; Pietrantonio F
    ESMO Open; 2022 Feb; 7(1):100380. PubMed ID: 35093742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.